(Q29397593)

ORCID Public Data File 2021

14 April 2017

0 references

1 reference

Tadej Battelino

1 reference

ORCID Public Data File 2021

Beat Neuenschwander

object named as

Beat Neuenschwander

1

0 references

author name string

Gorana Capkun-Niggli

2

1 reference

14 April 2017

Michael Branson

3

1 reference

14 April 2017

David J Spiegelhalter

4

1 reference

14 April 2017

publication date

February 2010

1 reference

14 April 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

Clinical Trials

1 reference

14 April 2017

volume

7

1 reference

14 April 2017

page(s)

5-18

1 reference

14 April 2017

issue

1

1 reference

The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design

14 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Regulatory approvals in a large multinational clinical trial: the ESPRIT experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Crossing international boundaries: implications for the Term Breech Trial Data Coordinating Centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The role of the data coordinating center in the IRB review and approval process: the DIG trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Study conduct, monitoring and data management in a trinational trial: the OPTIMA model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Experiences and challenges in data monitoring for clinical trials within an international tropical disease research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The International Consortium on Mental Health Policy and Services: objectives, design and project implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Quality control of phenotypic forms data in the Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Collection and processing of whole blood for transformation of peripheral blood mononuclear cells and extraction of DNA: the Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

HLA genotyping in the international Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Overview of the Rapid Response data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Biobanking, consent, and commercialization in international genetics research: the Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774510373497

The combination of randomized and historical controls in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Using historical controls in the analysis of developmental toxicity data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Use of historical controls in time-adjusted trend tests for carcinogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

On the use of historical control data in pre-clinical safety studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Projection from previous studies: a Bayesian and frequentist compromise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Incorporating historical control data in planning phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Borrowing strength from external trials in a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Using prior distributions to synthesize historical evidence: comments on the Goodman-Sladky case study of IVIg in Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Robust Bayesian methods for monitoring clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

On the Use of Historical Control Data to Estimate Dose Response Trends in Quantal Bioassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Bias modelling in evidence synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Meta-analysis: formulating, evaluating, combining, and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Advanced methods in meta-analysis: multivariate approach and meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

A re-evaluation of random-effects meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Bayesian approaches to random-effects meta-analysis: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Bayesian methods for cluster randomized trials with continuous responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

A likelihood approach to meta-analysis with random effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Meta-analysis in the design and monitoring of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Random-effects model for meta-analysis of clinical trials: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Determining the effective sample size of a parametric prior

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774509356002

Overview of the MHC fine mapping data

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2917852

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20603248

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20603248

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1740774509356002

1 reference

14 April 2017

10.1177/1740774510373497

1 reference

Consolidated OpenCitations Corpus – April 2017

3427494

3427494

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

0 references

1 reference